Clinical Trials
Enrolling Trials
1-7 of 7
for
"breast cancer"
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Gokalp Yasar, Demet
Breast - Breast
Adult
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
Craig, Chani L
(715) 358-1838
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
Eau Claire Center
2116 Craig Rd
Eau Claire, WI 54701
Ladysmith Center
906 College Ave W
Ladysmith, WI 54848
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
Stevens Point Center
,
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI 54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
EA1151, Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Onitilo, Adedayo A
Cancer Prevention - Breast
Adult
To compare the proportions of participants in the Tomosynthesis (TM) and Digital Mammography (DM) study arms experiencing the occurrence of an advanced breast cancer at any time during a period of 4.5 years from randomization,including the period of active screening and a period of clinical follow-up after the last screen (T4).
Bello, Tolulope O
(715) 221-7267
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
EA1181, (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Fagbemi, Seth O
Breast - Breast
Adult
To determine if 3-year recurrence-free survival (RFS) is greater than 92% among clinical stages II or IIIa patients with HER2-positive breast cancer who achieve pCR (ypT0/is ypN0) after preoperative therapy with 12 weeks of a taxane, trastuzumab (or FDA approved biosimilar) and pertuzumab (THP x 12). Post-operatively, patients will receive standard of care adjuvant locoregional therapy, plus completion of 12 months of HER2-targeted therapy (and standard adjuvant endocrine therapy as appropriate).
Revels, Cheryl M
(715) 389-4177
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
Eau Claire Center
2116 Craig Rd
Eau Claire, WI 54701
Ladysmith Center
906 College Ave W
Ladysmith, WI 54848
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
Stevens Point Center
,
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI 54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
NRG-BR003, A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Naqvi, Sm Bilal H
Breast - Breast
Adult
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.
Revels, Cheryl M
(715) 389-4177
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
Ladysmith Center
906 College Ave W
Ladysmith, WI 54848
Marshfield Clinic Cancer Care At St Michaels
900 ILLINOIS AVE
STEVENS POINT, WI 54481
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
Mfld Clinic Cancer Care at Sacred Heart Hospital
900 W CLAIREMONT AVE
EAU CLAIRE, WI 54701
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI 54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
Bauer, Anderson
Breast - Breast
Adult
This phase II trial studies how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy with or without olaparib may work better in treating patients with inflammatory breast cancer.
Diagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI 54476
Marshfield Clinic Cancer Center - Eau Claire
2200 Craig Road
Eau Claire, WI 54701
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
Stevens Point Center
,
The CompassHER2 Trials (Comprehensive Use of
Pathologic Response Assessment to Optimize Therapy in
HER2-Positive Breast Cancer) CompassHER2 Residual
Disease (RD), a Double-Blinded, Phase III Randomized
Trial of T-DM1 Compared With T-DM1 and Tucatinib
Husak, Michael
Breast - Breast
Adult
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Marshfield Clinic Cancer Center - Eau Claire
2200 Craig Road
Eau Claire, WI 54701
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
Stevens Point Center
,
Weston Center
3501 CRANBERRY BLVD
WESTON, WI 54476
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
Abdelhadi, Kareem H
Breast - Breast
Adult
This phase II trial studies how well FDG-PET/CT works in assessing the response of patients with breast cancer that has spread to the bones or mostly to the bones (bone-dominant metastatic breast cancer). Diagnostic procedures, such as FDG-PET/CT, may work better in measuring breast cancer activity before and after treatment compared to other standard imaging tests.
Hurley, Alexa A
(715) 393-1019
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
Eau Claire Center
2116 Craig Rd
Eau Claire, WI 54701
Ladysmith Center
906 College Ave W
Ladysmith, WI 54848
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
Stevens Point Center
,
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI 54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494